Kaitlyn D’Onofrio

DocwireNews

A study examined functional outcomes over five years correlated with five different treatments for localized prostate cancer.It is critical for patients to understand possible adverse effects associated with contemporary cancer treatments, according to the researchers, because this will help them make informed treatment decisions.To that end, the study authors performed a prospective, population-based cohort study on patients with favorable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] &le;20 ng/mL, and Grade Group 1-2) prostate cancer (n = 1,386) and unfavorable-risk (clinical stage cT2cN0M0, PSA of 20-50 ng/mL, or Grade Group 3-5) prostate cancer (n = 619) who were diagnosed between 2011 and 2012. Patients were recruited from five Surveillance, Epidemiology and End Results Program sites and a U.S. prostate cancer registry. The following treatments were evaluated in favorable-risk disease patients: active surveillance (n&thinsp;=&thinsp;363), nerve-sparing <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/multiquadrant-combined-robotic-radical-prostatectomy-and-left-partial-nephrectomy-a-combined-procedure-by-a-single-approach/">prostatectomy</a> (n&thinsp;=&thinsp;675), external beam radiation therapy (EBRT; n&thinsp;=&thinsp;261), and low-dose-rate brachytherapy (n&thinsp;=&thinsp;87). Men with unfavorable-risk disease received either <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/prostate-cancer-patients-prostatectomy/">prostatectomy</a> (n&thinsp;=&thinsp;402) or EBRT with androgen deprivation therapy (n&thinsp;=&thinsp;217). The primary outcome was patient-reported function five years after treatment, measured using the 26-item Expanded Prostate Index Composite. The researchers employed adjusted regression models for baseline function and patient and tumor characteristics. The following minimum clinically important differences were established: sexual function, 10 to 12; urinary incontinence, 6 to 9; urinary irritative symptoms, 5 to 7; and bowel and hormonal function, 4 to 6.<h2>Prostate Cancer Outcomes Differ by Risk</h2>Final analysis included completed data from 2,005 patients (median [interquartile range] age, 64 [59-70] years; 1,993 [77%] were non-Hispanic white). Nerve-sparing prostatectomy, compared to active surveillance, resulted in poorer five-year urinary incontinence (adjusted mean difference, &ndash;10.9; 95% confidence interval [CI], &ndash;14.2 to &ndash;7.9) and three-year sexual function (adjusted mean difference, &ndash;15.2; 95% CI, &ndash;18.8 to &ndash;11.5). Low-dose-rate brachytherapy, compared to <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/long-term-outcomes-of-active-surveillance-for-prostate-cancer-the-memorial-sloan-kettering-cancer-center-experience/">active surveillance</a>, was predictive of worse one-year urinary irritative (adjusted mean difference, &ndash;7.0; 95% CI, &ndash;10.1 to &ndash;3.9), sexual (adjusted mean difference, &ndash;10.1; 95% CI, &ndash;14.6 to &ndash;5.7), and bowel (adjusted mean difference, &ndash;5.0; 95% CI, &ndash;7.6 to &ndash;2.4) function. EBRT in favorable-disease men did not largely differ from active surveillance at any point in the study in terms of urinary, sexual, and bowel function changes.In the unfavorable-risk disease group, EBRT with ADT, compared to prostatectomy, resulted in worse six-month hormonal function (adjusted mean difference, &ndash;5.3; 95% CI, &ndash;8.2 to &ndash;2.4) and one-year bowel function (adjusted mean difference, &ndash;4.1; 95% CI, &ndash;6.3 to &ndash;1.9), but better five-year sexual function (adjusted mean difference, 12.5; 95% CI, 6.2&ndash;18.7) and incontinence at every time point over the five-year study period (adjusted mean difference, 23.2; 95% CI, 17.7&ndash;28.7).The study results were published in <a href="https://jamanetwork.com/journals/jama/article-abstract/2758599">JAMA</a>.The researchers summarized, &ldquo;In this cohort of men with localized prostate cancer, most functional differences associated with contemporary management options attenuated by 5 years. However, men undergoing prostatectomy reported clinically meaningful worse incontinence through 5 years compared with all other options, and men undergoing prostatectomy for unfavorable-risk disease reported worse sexual function at 5 years compared with men who underwent EBRT with ADT.&rdquo;

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Here Are The Possible Five-year Effects Associated with Five Treatments for Localized Prostate Cancer

Oncology

A study examined functional outcomes over five years correlated with five different treatments for localized prostate cancer. ...

Here Are The Possible Five-year Effects Associated with Five Treatments for Localized Prostate

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe